Temsirolimus (CCI-779) is an inhibitor of mammalian target of rapamycin (mTOR) kinase, a component of intracellular signaling pathways involved in the growth and proliferation of cells 10,11 and ...

From such efforts, temsirolimus emerged, rapidly gaining regulatory approval for the management of advanced renal cell carcinoma. Laura Boehnke Michaud News News ...

Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor and rapamycin analogue that is approved for treating advanced renal cell carcinoma (RCC). It is being actively evaluated in ...

Temsirolimus (formerly known as CCI-779) blocks the function of the mammalian target of rapamycin (mTOR), a key protein within cells that regulates cell proliferation, growth and survival.

The objective of this study was to characterise the mechanism underlying acquired resistance to temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), in renal cell carcinoma (RCC). A ...

June 29, 2007 (Chicago) -- Two new analyses of a phase 3 trial of temsirolimus ( Torisel, Wyeth) show the drug improves overall survival in patients with clear cell and other tumor cell types, and ...

Temsirolimus, for the treatment of renal cancer, is now available in the U.S. from Fresenius Kabi. It is the latest addition to the company's large U.S. portfolio of generic injectable oncology ...

A phase 3 trial found that temsirolimus improved overall survival in patients with advanced renal cell cancer, as compared with standard therapy with interferon alfa.

Oncology/Hematology > Other Cancers Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer — Adding the mTOR inhibitor didn't improve EFS in intermediate-risk rhabdomyosarcoma ...

Temsirolimus (formerly known as CCI-779) blocks the function of the mammalian target of rapamycin (mTOR), a key protein within cells that regulates cell proliferation, growth and survival.

Temsirolimus produced an objective response rate of 9.2% (10 partial responses) in the intent-to-treat population. Median time to tumor progression was 12.0 weeks. Efficacy was similar for both dose ...

Adventitial delivery of temsirolimus appears to safely reduce neointimal hyperplasia and target lesion failure after endovascular revascularization of below-the-knee (BTK) arteries, according to a ...